生物制剂在口腔扁平苔藓治疗中的应用

doi:10.13591/j.cnki.kqyx.2022.03.014

Abstract

Abstract: Oral lichen planus (OLP) is a chronic inflammatory disease of unknown etiology, and is closely related to autoimmunity. Corticosteroids and immunosuppressants are commonly used drugs for OLP treatment, but some OLP patients show insensitivity or treatment resistance. Research suggests that biologics have advantages for OLP patients that are not sensitive or are resistant to conventional drug treatment. This article reviews the types, mechanisms, efficacy, prognosis, and adverse reactions of biologics for OLP treatment and provides references for the treatment of OLP.

Key words: oral lichen planus, biologics, treatment

CLC Number:

R781.5

SUN Yutong, JIANG Lu. Role of biologics in the treatment of oral lichen planus[J]. Stomatology, 2022, 42(3): 261-265.

References

[1] Olson MA, Rogers RSⅢ, Bruce AJ. Oral lichen planus[J]. Clin Dermatol, 2016, 34(4):495-504.
[2] Alrashdan MS, Cirillo N, McCullough M. Oral lichen planus:A literature review and update[J]. Arch Dermatol Res, 2016, 308(8):539-551.
[3] Carrozzo M, Porter S, Mercadante V,et al. Oral lichen planus:A disease or a spectrum of tissue reactions? Types, causes, diagnostic algorhythms, prognosis, management strategies[J]. Periodontol 2000, 2019, 80(1):105-125.
[4] Nogueira PA, Carneiro S, Ramos-e-Silva M. Oral lichen planus:An update on its pathogenesis[J]. Int J Dermatol, 2015, 54(9):1005-1010.
[5] Kurago ZB. Etiology and pathogenesis of oral lichen planus:An overview[J]. Oral Surg Oral Med Oral Pathol OralRadiol, 2016, 122(1):72-80.
[6] Gupta S, Ghosh S, Gupta S. Interventions for the management of oral lichen planus:A review of the conventional and novel therapies[J]. Oral Dis, 2017, 23(8):1029-1042.
[7] Rønholt K, Iversen L. Old and new biological therapies for psoriasis[J]. Int J Mol Sci, 2017, 18(11):E2297.
[8] Speeckaert R, Lambert J, van Geel N. Learning from success and failure:Biologics for non-approved skin diseases[J]. Front Immunol, 2019, 10:1918.
[9] Joly P, Maho-Vaillant M, Prost-Squarcioni C,et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of Pemphigus (Ritux 3):A prospective, multicentre, parallel-group, open-label randomised trial[J]. Lancet, 2017, 389(10083):2031-2040.
[10] Torres J, Mehandru S, Colombel JF,et al. Crohn's disease[J]. Lancet, 2017, 389(10080):1741-1755.
[11] Heelan K, McAleer MA, Roche L,et al. Intractable erosive lichen planus treated successfully with rituximab[J]. Br J Dermatol, 2015, 172(2):538-540.
[12] Mahmoud MM, Afifi MM. Anti-angiogenic therapy (bevacizumab) in the management of oral lichen planus[J]. Eur J Oral Sci, 2016, 124(2):119-126.
[13] Fivenson DP, Mathes B. Treatment of generalized lichen planus with alefacept[J]. Arch Dermatol, 2006, 142(2):151-152.
[14] Chang AL, Badger J, Rehmus W,et al. Alefacept for erosive lichen planus:A case series[J]. J Drugs Dermatol, 2008, 7(4):379-383.
[15] Cheng A, Mann C. Oral erosive lichen planus treated with efalizumab[J]. Arch Dermatol, 2006, 142(6):680-682.
[16] Heffernan MP, Smith DI, Bentley D,et al. A single-center, open-label, prospective pilot study of subcutaneous efalizumab for oral erosive lichen planus[J]. J Drugs Dermatol, 2007, 6(3):310-314.
[17] Jones-Hughes T, Snowsill T, Haasova M,et al. Immunosuppressive therapy for kidney transplantation in adults:A systematic review and economic model[J]. Health Technol Assess, 2016, 20(62):1-594.
[18] Wang K, Xu X, Fan M. Induction therapy of basiliximab versus antithymocyte globulin in renal allograft:A systematic review and meta-analysis[J]. Clin Exp Nephrol, 2018, 22(3):684-693.
[19] Rebora A, Parodi A, Murialdo G. Basiliximab is effectivefor erosive lichen planus[J]. Arch Dermatol, 2002, 138(8):1100-1101.
[20] MacIsaac J, Siddiqui R, Jamula E,et al. Systematic review of rituximab for autoimmune diseases:A potential alternative to intravenous immune globulin[J]. Transfusion, 2018, 58(11):2729-2735.
[21] Parmentier L, Bron BA, Prins C,et al. Mucocutaneous lichen planus with esophageal involvement:Successful treatment with an anti-CD20 monoclonal antibody[J]. Arch Dermatol, 2008, 144(11):1427-1430.
[22] Salles G, Barrett M, Foà R,et al. Rituximab in B-cell hematologic malignancies:A review of 20 years of clinical experience[J]. Adv Ther, 2017, 34(10):2232-2273.
[23] Mitoma H, Horiuchi T, Tsukamoto H, et al. Molecular mechanisms of action of anti-TNF-α agents-Comparison among therapeutic TNF-α antagonists[J]. Cytokine, 2018, 101:56-63.
[24] Yarom N. Etanercept for the management of oral lichen planus[J]. Am J Clin Dermatol, 2007, 8(2):121.
[25] Campanati A, Diotallevi F, Martina E,et al. Safety update of etanercept treatment for moderate to severe plaque psoriasis[J]. Expert Opin Drug Saf, 2020, 19(4):439-448.
[26] O'Neill ID, Scully C. Biologics in oral medicine:Ulcerative disorders[J]. Oral Dis, 2013, 19(1):37-45.
[27] Chao TJ. Adalimumab in the management of cutaneous and oral lichen planus[J]. Cutis, 2009, 84(6):325-328.
[28] Holló P, Szakonyi J, Kiss D,et al. Successful treatment of lichen planus with adalimumab[J]. Acta Derm Venereol, 2012, 92(4):385-386.
[29] Inoue-Nishimoto T, Hanafusa T, Igawa K, et al. Possible association of anti-tumor necrosis factor-α antibody therapy with the development of scleroderma-like changes with lichen planus[J]. Eur J Dermatol, 2015, 25(5):513-515.
[30] Inoue A, Sawada Y, Yamaguchi T, et al. Lichenoid drug eruption caused by adalimumab:A case report and literature review[J]. Eur J Dermatol, 2017, 27(1):69-70.
[31] Li MG, Kroetz DL. Bevacizumab-induced hypertension:Clinical presentation and molecular understanding[J].Pharmacol Ther, 2018, 182:152-160.
[32] Chiang CP, Yu-Fong Chang J, Wang YP,et al. Oral lichen planus-Differential diagnoses, serum autoantibodies, hematinic deficiencies, and management[J]. J Formos Med Assoc, 2018, 117(9):756-765.
[33] 傅志华, 武照, 李乾鹏, 等. 血管生成与口腔扁平苔藓关系的研究进展[J]. 口腔医学, 2019, 39(8):757-761.
[34] Succaria F, Bhawan J. Cutaneous side-effects of biologics in immune-mediated disorders:A histopathological perspective[J]. J Dermatol, 2017, 44(3):243-250.
[35] Andrade P, Lopes S, Albuquerque A, et al. Oral lichen planus in IBD patients:A paradoxical adverse effect of anti-TNF-α therapy[J]. Dig Dis Sci, 2015, 60(9):2746-2749.

Role of biologics in the treatment of oral lichen planus

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	FAN Dian, LIU Hao, YUAN Changyong, WANG Penglai. Factors influencing mechanical properties of clear aligners and research progress [J]. Stomatology, 2023, 43(3): 278-281.
[2]	JIN Zuolin. Early treatment based on the basic theory of malocclusion [J]. Stomatology, 2023, 43(3): 193-196.
[3]	YANG Xia, YE Qingyuan, SONG Changlong, HOU Rui, YANG Yaowu, WEI Jianhua. Progress of research on diagnosis and treatment of the first bite syndrome [J]. Stomatology, 2023, 43(2): 188-192.
[4]	DAI Anna,DING Peihui. Periodontal therapy for stage Ⅳ grade C generalized periodontitis: A case report of 7-year follow-up [J]. Stomatology, 2023, 43(2): 145-152.
[5]	XIANG Yanyan, SONG Dongsheng, WANG Shaotai, WANG Min. Aesthetic considerations of anterior zone in oral treatment [J]. Stomatology, 2022, 42(9): 838-841.
[6]	LI Kaiyi, HE Wenxiu, REN Xiaomeng, LUO Haiyan, LI Chunlei, HUA Hong. Clinical and histopathological characteristics of oral lichen planus patients with type 2 diabetes mellitus [J]. Stomatology, 2022, 42(9): 802-806.
[7]	SONG Ye, HAN Jingying. Progress of research on the influence of extraction mode of premolars on Bolton ratio in orthodontics [J]. Stomatology, 2022, 42(9): 856-859.
[8]	SHEN Yiyang, FENG Xiaoyan, ZHANG Chenxing, LI Juan, LIN Jun. Digital multidisciplinary treatment of an adult patient with high-angle skeletal Class Ⅱ malocclusion and obstructive sleep apnea hypopnea syndrome [J]. Stomatology, 2022, 42(9): 824-830.
[9]	DU Yaxin. Progress of research on the adhesive property of novel resin-ceramic hybrid material [J]. Stomatology, 2022, 42(8): 764-768.
[10]	WU Qirong, LEI Chen, WU Di, ZHOU Heyang, TANG Chunbo. Construction and antibacterial property of funme peptide coating on titanium surface [J]. Stomatology, 2022, 42(7): 582-586.
[11]	GAO Lei, JIANG Yinhua. Research progress of intra-articular pressure of temporomandibular joint [J]. Stomatology, 2022, 42(7): 668-672.
[12]	ZHOU Wei, WANG Lin, WANG Liang, ZHAO Chunyang. Study on root resorption of adjacent incisors after traction treatment of maxillary impacted canines [J]. Stomatology, 2022, 42(6): 525-528.
[13]	FENG Fan, LIU Xiaqing, LI Yadan, LIU Henan, QIAO Yuxuan, LI Ying. Research progress of Er: YAG laser pretreatment methods of post space [J]. Stomatology, 2022, 42(5): 467-470.
[14]	LIANG Yan, XU Zinan, CAI Mingxiang, LIU Xiangning. Applications and research progress of aptamerin stomatology [J]. Stomatology, 2022, 42(4): 358-361.
[15]	ZHANG Xuelian, GUAN Cuiqiang, JIN Enlong. Correlation between 4-1BB and CD8 expression in oral lichen planus [J]. Stomatology, 2022, 42(4): 296-299.